Atopic Dermatitis (AD) or Eczema is a multifactorial disease and its pathophysiology has been linked to (genetic) modification of skin barrier function, bacterial (e.g. Staphylococcus aureus) colonisation and inflammation (Ref 7, 10, 11). It has a lifetime prevalence of 7% (Ref 7).
AD patients complain of dry, inflamed and itchy skin that typically affects the face, inside of the elbows and back of the knees. The current US cost of treatment for atopic dermatitis amounts to $12 billion per year (Ref 7). 75% of the costs are indirect costs e.g. over the counter remedies, lubricants and days lost from work. Such treatments can help in symptom relief but do not tackle the underlying disease. Current second line treatments are topical corticosteroids with third line topical calcineurin inhibitors. These treatments are unpopular because of their significant side effects. What patients want is a safe, effective treatment that can be used in all age groups.
Blueberry Therapeutics is developing a new treatment using a potent, selective inhibitor (BB2702) of one of the key inflammatory pathways in AD. Together with our effective bacteriocidal nanopolymer delivery system this treatment will address two of the three key mechanisms of AD: inflammation, and bacterial colonisation.
7. NIAMS, August 2011. http://www.niams.nih.gov/Health_Info/Atopic_Dermatitis/default.asp
8. Bieber T. Atopic Dermatitis. N Engl J Med 2008; 358: 1483-1494
9. Leung DY, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-657
10. Wise RD. A review of atopic dermatitis. Compr Ther 2006; 32: 111-117
11. Lane JE, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54: 68-72